<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">
 

Models of the Month

Discover some of our popular patient-relevant models and gain a significant advantage in your team's preclinical oncology studies with time and cost savings.

Current Highlights

Access diverse and well-characterized tumor models, along with extensive profiling and pharmacologic data, empowering researchers like you to make confident and well-informed decisions during oncology drug discovery.

October 2026

BR9465  BR5017,  BR5012, BR10564
Breast Cancer Models
This model series features four matched breast cancer organoid and PDX models spanning a range of HER2 expression levels. It enables researchers to explore target expression and ADC activity across in vitro and in vivo systems, including response to DS-8201. All four PDX models showed sensitivity, with tumor growth inhibition ranging from 88% to 100%, including in HER2-low and HER2-negative models.

Previous Model Highlights

Look back at our previous models to meet your research needs

September 2026
September 2026

In Vivo and In Vitro Models - Matched PDX/PDXO Model Series

GA0091, GA6833, GA0087, GA0089, GA0429, GA6891, GA6877, GA6866, GA6815, GA3102
Gastric Cancer Models

This model series provides matched gastric PDX and PDXO models that allow target expression, ADC activity, and in vitro-to-in vivo translation to be evaluated within the same underlying tumor biology.

August 2026

In Vivo Models

LU9901, LU9906, and LU9903

In Vitro Models

LU11786B, LU9906B
Lung Cancer Models

An isogenic LU11786B lung cancer organoid pair engineered through TROP2 knockout to model Datroway resistance. The models demonstrate target-driven resistance, with loss of TROP2 abolishing detectable Datroway binding and associated DNA damage while retaining DXd payload activity. Clinically pretreated NSCLC PDX models LU9901, LU9906, and LU9903, with corresponding LU9906B organoid data, further recapitulate resistance observed in patients to osimertinib-based therapy and earlier ALK inhibitors.

July 2026

In Vivo Models

BR9690 / BR9806 / BR9801

In Vitro Models

BR9690B / BR9806B / BR9801B
Longitudinal TNBC PDX/PDXO Series

Three matched PDX and organoid models established from consecutive tumor samples from the same TNBC patient during disease progression, including post-Trodelvy (sacituzumab govitecan) treatment. The models recapitulate resistance to Dato-DXd in both In Vitro and In Vivo.

June 2026

In Vivo Models

CR9831

CR9831 is a colorectal cancer PDX derived from a heavily pretreated patient, featuring prior exposure to an anti-c-MET ADC.

In Vitro Models

PA20006B

Intra-patient organoid models allow for more accurate recapitulation of parental tumors. Highlighted here is primary site pancreatic organoid model PA20006B taken from a patient.

August 2026
September 2026

In Vivo and In Vitro Models - Matched PDX/PDXO Model Series

GA0091, GA6833, GA0087, GA0089, GA0429, GA6891, GA6877, GA6866, GA6815, GA3102
Gastric Cancer Models

This model series provides matched gastric PDX and PDXO models that allow target expression, ADC activity, and in vitro-to-in vivo translation to be evaluated within the same underlying tumor biology.

August 2026

In Vivo Models

LU9901, LU9906, and LU9903

In Vitro Models

LU11786B, LU9906B
Lung Cancer Models

An isogenic LU11786B lung cancer organoid pair engineered through TROP2 knockout to model Datroway resistance. The models demonstrate target-driven resistance, with loss of TROP2 abolishing detectable Datroway binding and associated DNA damage while retaining DXd payload activity. Clinically pretreated NSCLC PDX models LU9901, LU9906, and LU9903, with corresponding LU9906B organoid data, further recapitulate resistance observed in patients to osimertinib-based therapy and earlier ALK inhibitors.

July 2026

In Vivo Models

BR9690 / BR9806 / BR9801

In Vitro Models

BR9690B / BR9806B / BR9801B
Longitudinal TNBC PDX/PDXO Series

Three matched PDX and organoid models established from consecutive tumor samples from the same TNBC patient during disease progression, including post-Trodelvy (sacituzumab govitecan) treatment. The models recapitulate resistance to Dato-DXd in both In Vitro and In Vivo.

June 2026

In Vivo Models

CR9831

CR9831 is a colorectal cancer PDX derived from a heavily pretreated patient, featuring prior exposure to an anti-c-MET ADC.

In Vitro Models

PA20006B

Intra-patient organoid models allow for more accurate recapitulation of parental tumors. Highlighted here is primary site pancreatic organoid model PA20006B taken from a patient.

July 2026
September 2026

In Vivo and In Vitro Models - Matched PDX/PDXO Model Series

GA0091, GA6833, GA0087, GA0089, GA0429, GA6891, GA6877, GA6866, GA6815, GA3102
Gastric Cancer Models

This model series provides matched gastric PDX and PDXO models that allow target expression, ADC activity, and in vitro-to-in vivo translation to be evaluated within the same underlying tumor biology.

August 2026

In Vivo Models

LU9901, LU9906, and LU9903

In Vitro Models

LU11786B, LU9906B
Lung Cancer Models

An isogenic LU11786B lung cancer organoid pair engineered through TROP2 knockout to model Datroway resistance. The models demonstrate target-driven resistance, with loss of TROP2 abolishing detectable Datroway binding and associated DNA damage while retaining DXd payload activity. Clinically pretreated NSCLC PDX models LU9901, LU9906, and LU9903, with corresponding LU9906B organoid data, further recapitulate resistance observed in patients to osimertinib-based therapy and earlier ALK inhibitors.

July 2026

In Vivo Models

BR9690 / BR9806 / BR9801

In Vitro Models

BR9690B / BR9806B / BR9801B
Longitudinal TNBC PDX/PDXO Series

Three matched PDX and organoid models established from consecutive tumor samples from the same TNBC patient during disease progression, including post-Trodelvy (sacituzumab govitecan) treatment. The models recapitulate resistance to Dato-DXd in both In Vitro and In Vivo.

June 2026

In Vivo Models

CR9831

CR9831 is a colorectal cancer PDX derived from a heavily pretreated patient, featuring prior exposure to an anti-c-MET ADC.

In Vitro Models

PA20006B

Intra-patient organoid models allow for more accurate recapitulation of parental tumors. Highlighted here is primary site pancreatic organoid model PA20006B taken from a patient.

June 2026
September 2026

In Vivo and In Vitro Models - Matched PDX/PDXO Model Series

GA0091, GA6833, GA0087, GA0089, GA0429, GA6891, GA6877, GA6866, GA6815, GA3102
Gastric Cancer Models

This model series provides matched gastric PDX and PDXO models that allow target expression, ADC activity, and in vitro-to-in vivo translation to be evaluated within the same underlying tumor biology.

August 2026

In Vivo Models

LU9901, LU9906, and LU9903

In Vitro Models

LU11786B, LU9906B
Lung Cancer Models

An isogenic LU11786B lung cancer organoid pair engineered through TROP2 knockout to model Datroway resistance. The models demonstrate target-driven resistance, with loss of TROP2 abolishing detectable Datroway binding and associated DNA damage while retaining DXd payload activity. Clinically pretreated NSCLC PDX models LU9901, LU9906, and LU9903, with corresponding LU9906B organoid data, further recapitulate resistance observed in patients to osimertinib-based therapy and earlier ALK inhibitors.

July 2026

In Vivo Models

BR9690 / BR9806 / BR9801

In Vitro Models

BR9690B / BR9806B / BR9801B
Longitudinal TNBC PDX/PDXO Series

Three matched PDX and organoid models established from consecutive tumor samples from the same TNBC patient during disease progression, including post-Trodelvy (sacituzumab govitecan) treatment. The models recapitulate resistance to Dato-DXd in both In Vitro and In Vivo.

June 2026

In Vivo Models

CR9831

CR9831 is a colorectal cancer PDX derived from a heavily pretreated patient, featuring prior exposure to an anti-c-MET ADC.

In Vitro Models

PA20006B

Intra-patient organoid models allow for more accurate recapitulation of parental tumors. Highlighted here is primary site pancreatic organoid model PA20006B taken from a patient.

September 2026

In Vivo and In Vitro Models - Matched PDX/PDXO Model Series

GA0091, GA6833, GA0087, GA0089, GA0429, GA6891, GA6877, GA6866, GA6815, GA3102
Gastric Cancer Models

This model series provides matched gastric PDX and PDXO models that allow target expression, ADC activity, and in vitro-to-in vivo translation to be evaluated within the same underlying tumor biology.

August 2026

In Vivo Models

LU9901, LU9906, and LU9903

In Vitro Models

LU11786B, LU9906B
Lung Cancer Models

An isogenic LU11786B lung cancer organoid pair engineered through TROP2 knockout to model Datroway resistance. The models demonstrate target-driven resistance, with loss of TROP2 abolishing detectable Datroway binding and associated DNA damage while retaining DXd payload activity. Clinically pretreated NSCLC PDX models LU9901, LU9906, and LU9903, with corresponding LU9906B organoid data, further recapitulate resistance observed in patients to osimertinib-based therapy and earlier ALK inhibitors.

July 2026

In Vivo Models

BR9690 / BR9806 / BR9801

In Vitro Models

BR9690B / BR9806B / BR9801B
Longitudinal TNBC PDX/PDXO Series

Three matched PDX and organoid models established from consecutive tumor samples from the same TNBC patient during disease progression, including post-Trodelvy (sacituzumab govitecan) treatment. The models recapitulate resistance to Dato-DXd in both In Vitro and In Vivo.

June 2026

In Vivo Models

CR9831

CR9831 is a colorectal cancer PDX derived from a heavily pretreated patient, featuring prior exposure to an anti-c-MET ADC.

In Vitro Models

PA20006B

Intra-patient organoid models allow for more accurate recapitulation of parental tumors. Highlighted here is primary site pancreatic organoid model PA20006B taken from a patient.

Ready To Collaborate?

Access a diverse range of tumor models and data, all in one integrated platform, empowering your research endeavors.

Boasting over 2,500 Patient-Derived Xenograft (PDX) models — the world's largest.

Our collection also includes 100+ immuno-oncology murine models, 600+ organoid models, 1,000+ cancer cell lines, and 200+ CDX models, ensuring a perfect fit for your research needs.